Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2020 Jun 16

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Panminerva Medica 2020 Jun 16

DOI: 10.23736/S0031-0808.20.03999-3

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

The thromboembolism in COVID-19: the unsolved problem

Matteo CASALE 1, Giuseppe DATTILO 2, Egidio IMBALZANO 2, Marianna GIGLIOTTI DE FAZIO 2, Claudia MORABITO 2, Maurizio MEZZETTI 1, Paolo BUSACCA 1, Salvatore S. SIGNORELLI 3, Natale D. BRUNETTI 4, Michele CORREALE 5

1 Hospital “S. Maria della Misericordia”, Operative Unit of ICCU and Cardiology, ASUR Marche - Area Vasta 1, Urbino, Italy; 2 Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 3 Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 4 Department of Medical and Surgical Sciences, Università degli Studi di Foggia, Foggia, Italy; 5 Cardiology Unit, University Hospital Policlinico Riuniti, Foggia, Italy


PDF


INTRODUCTION: The recent Sars-Cov-2 pandemic (COVID-19) has led to growing research to explain the poor clinical prognosis in some patients.
EVIDENCE ACQUISITION: While early observational studies highlighted the role of the virus in lung failure, in a second moment thrombosis emerged as a possible explanation of the worse clinical course in some patients. Despite initial difficulties in management of such patients, the constant increase of literature in the field is to date clarifying some questions from clinicians. However, several other questions need answer.
EVIDENCE SYNTHESIS: A novel disease (Covid-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was responsible for thousands of hospitalizations for severe acute respiratory syndrome, with several cases of thrombotic complications due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. Covid-19 and hospitalizations for Covid-19 may carry several potential risk factors for thrombosis. Severe coagulation abnormalities may occur in almost all of the severe and critical ill COVID-19 cases.
CONCLUSIONS: Despite a strong pathophysiological rationale, the evidences in literature are not enough to recommend an aggressive antithrombotic therapy in COVID- 19. However, it is our opinion that an early use, even at home at the beginning of the disease, could improve the clinical course.


KEY WORDS: Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Thromboembolism; Thrombosis, low molecular weight heparin

top of page